Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial

NCT02467582 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT02467582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02467582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 3
Overall status
Terminated
Start date
June 9, 2016
Completion date
September 14, 2023
Enrollment
1,040 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer